Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.

Alberto Garaventa,Ulrike Poetschger,Dominique Valteau-Couanet,Roberto Luksch,Victoria Castel,Martin Elliott,Shifra Ash,Godfrey Chi-Fung Chan,Genevieve Laureys,Maja Beck Popovic,Kim Vettenranta,Walentyna Balwierz,Henrik Schroeder,Cormac Owens,Maja Cesen,Vassilios Papadakis,Toby Trahair,Gudrun Schleiermacher,Peter F. Ambros,Stefania Sorrentino,Andrew D.J. Pearson,Ruth Ladenstein

Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.

2021

PURPOSEInduction therapy is a critical component of the therapy of high-risk neuroblastoma. We aimed to assess if the Memorial Sloan Kettering Cancer Center (MSKCC) N5 induction regimen (MSKCC-N5) ...

Keywords:

Neuroblastoma
Oncology
Internal medicine
Medicine
Cancer
induction therapy
Pediatric oncology
Randomized controlled trial
Regimen
group study
high risk neuroblastoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations